QTc prolongation and high-dose olanzapine [3]

Psychosomatics

Volumn 44, Issue 2, 2003, Pages 174-175

  Dineen, Sean ^a   Withrow, Kirk ^a   Voronovitch, Liouda ^a   Munshi, Firoz ^a   Wally Nawbary, Mohammad ^a   Lippmann, Steven ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADULT; CASE REPORT; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HUMAN; LABORATORY TEST; LETTER; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT INTERVAL;

EID: 0037369177     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.44.2.174     Document Type: Letter

References (5)

1. Tan HL, Hou CJ, Lauer MR, Sung RJ: Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995; 122:701-714
2. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA: Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67:774-776
3. Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001; 158:1774-1782
4. Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S: Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001; 62:191-198
5. Czekalla J, Kollack-Walker S, Beasley CM Jr: Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001; 62:35-40